How to access Rinvoq from Saudi Arabia — the named-patient import pathway, 2026

By Reserve Meds · Clinical & regulatory team · Last reviewed 2026-04-23

A Saudi patient with moderate-to-severe atopic dermatitis, rheumatoid arthritis, psoriatic arthritis, ulcerative colitis, Crohn's disease, or axial spondyloarthritis may receive a prescription for Rinvoq (upadacitinib) from their treating dermatologist, rheumatologist, or gastroenterologist. Rinvoq is FDA-approved in the United States and manufactured by AbbVie. It is an oral once-daily selective JAK1 inhibitor that has extended across multiple immune-mediated conditions. Access through Saudi hospital pharmacies varies by indication; when your indication is not on a formulary, or when the specific strength is not locally stocked, a named-patient import route remains legitimate.

This guide explains the pathway, what documentation your physician needs, typical costs and timing, and where Reserve Meds fits in.

The clinical situation

Rinvoq is an oral JAK1-selective inhibitor taken once daily. Dosing differs by indication — 15 mg is common for rheumatoid and psoriatic arthritis, higher strengths for inflammatory bowel disease induction. Eligibility considers prior therapy history, cardiovascular and malignancy risk screening in line with the FDA boxed warning (and updated EU labeling) applicable to the JAK class, and ongoing monitoring. Your physician will confirm baseline labs, TB screening, and vaccination status per FDA labeling.

Is Rinvoq legally importable into Saudi Arabia?

Yes — through the Saudi Food and Drug Authority (SFDA) named-patient / personal-use import framework. The pathway allows a Saudi-licensed physician to import a medicine not locally registered for the specific indication when: (a) the medicine is approved by a recognised reference authority such as the US FDA or EMA, (b) no clinically equivalent locally available alternative is suitable for the patient, (c) the physician takes clinical responsibility, and (d) chain of custody is documented.

Rinvoq is locally registered in Saudi Arabia for several indications, so many patients access it through hospital pharmacies. The named-patient pathway is relevant when the indication is outside the local label, when the specific strength is out of stock, or when institutional procurement timing is not clinically workable.

How the pathway works, step by step

1. Consultation with your treating physician. Clinical decision with documented severity and prior therapy history.
2. Confirming the import rationale. Indication, strength, or supply-gap rationale is documented.
3. SFDA named-patient application. The physician or hospital files the application with clinical rationale, patient reference, product details, and chain-of-custody plan.
4. US-side sourcing. Reserve Meds coordinates with our US-licensed specialty wholesale partner to secure product from authorised distribution.
5. Shipment. Rinvoq is an oral tablet with standard storage; shipment includes tamper-evident packaging and chain-of-custody documentation.
6. Arrival and first dose. The dispensing facility or pharmacy releases product against the physician's prescription.

What documentation your physician needs

Your physician will typically need to provide:

• Clinical rationale letter confirming diagnosis, severity, prior therapies, and Rinvoq as the indicated treatment
• Verification of their Saudi medical licence
• Patient identifier
• Pre-treatment screening confirmation (TB, lipids, infection screening per labeling)
• Planned dosing regimen and follow-up cadence

Reserve Meds provides a physician documentation kit that bundles the templates SFDA reviewers expect to see for JAK-class therapies, including the cardiovascular/malignancy-risk discussion expected for this class.

Costs and timing

Rinvoq's US cash-pay reference price for a 30-tablet month supply at 15 mg sits in a broad indicative range of roughly USD 6,500–7,500. Higher strengths cost more. International logistics, SFDA documentation handling, and concierge coordination add incremental cost. Reserve Meds issues a full transparent quote at the start of intake. These ranges are indicative, not guaranteed.

Indicative timing — not guaranteed — for first dose after cohort intake opens is approximately 10–21 days from the moment a complete application is submitted. Refills ship on a rolling basis.

Reserve Meds is in pre-launch. Fulfillment availability is limited to our first cohort, and all timelines published on this site are indicative. If your clinical situation is time-sensitive, flag that when you join the waitlist — we triage accordingly.

Reserve Meds's role

Reserve Meds is a US-based concierge coordinator for cross-border specialty medicine. For Rinvoq specifically, we provide:

• Sourcing. Through our US-licensed specialty wholesale partner, operating under DSCSA chain-of-custody.
• Documentation. Regulatory package for your physician and for SFDA review.
• Logistics. Tamper-evident, internationally tracked shipment.
• Concierge case lead. A named point of contact.

What we do not do: we are not the prescriber, we do not practise medicine, and we are not the dispensing pharmacy. All clinical decisions remain with your treating physician. We operate on a waitlist basis during pre-launch.

Frequently asked

Is this legal in Saudi Arabia? Yes, when executed through the SFDA named-patient / personal-use framework with appropriate documentation.

What about the JAK class warnings? The FDA boxed warning on JAK inhibitors (CV events, malignancy, thrombosis, serious infection) applies across the class. Your physician assesses risk-benefit and monitors per labeling.

Can a locally registered JAK work instead? Your physician will consider any locally registered alternative that fits your case. If the clinical rationale for Rinvoq specifically is documented, the named-patient pathway supports the gap.

Will private insurance cover this? Cash-pay is the default. Some insurers reimburse named-patient imports case by case; we supply documentation for your submission but do not process insurance claims directly.

Next step — join the first-cohort waitlist

Reserve Meds is opening to a limited first cohort in 2026. Add your case to the waitlist and our concierge case lead will reach out when we are ready to enter intake for Rinvoq coordination in Saudi Arabia.

Add me to the Rinvoq waitlist

---

> Examples and timings above are composite illustrations drawn from published sources and typical named-patient patterns. Your individual case is assessed by your physician and our clinical-regulatory team; Reserve Meds does not guarantee outcomes or timelines.

Clinical & regulatory review: Reserve Meds clinical team and AI regulatory-counsel review pipeline. Last medically reviewed: 2026-04-23.